Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Get approved Complete a quick online evaluation to determine if GLP-1 medication is right for you
Serious risks, though rare, include pancreatitis, gallbladder disease, and thyroid-related complications
Sources Food and Drug Administration (FDA): FDA Approves New Medication for Chronic Weight Management Molecular Metabolism Journal: Glucagon-like peptide 1 (GLP-1) American Gastroenterological Association (AGA): Biology of Incretins: GLP-1 and GIP Columbia Surgery: The Ozempic Effect: Everything You Need to Know About Medical Weight Loss Eli Lilly: Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies American Diabetes Association (ADA): Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Important Medical Information and Disclaimers Important Current Status Update : As of March 19, 2025, the FDA has ended enforcement discretion for compounded tirzepatide
Reserved for adults
Are exploring peptide supplementation under healthcare provider guidance
US$ 23.89
US$ 27.64
US$ 26.30
US$ 23.64
US$ 24.69
